Pharma Contract Manufacturing 2025 is taking place in Berlin next March (26-27th). Download the event details here: Ahead of ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3Munich, ...

Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The ...

Celerion, a global leader in early clinical research, is proud to announce its commitment to the Science Based Targets Initiative (SBTi), reinforcing its dedication to sustainable corporate climate ...

Diagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will ...

Elsevier, a global leader in information and analytics, and Enamine, a global leader in supplying small molecules and early drug discovery services, have announced a partnership to integrate Enamine’s ...

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private ...

Refoxy Pharmaceuticals GmbH is a preclinical biotech company developing small molecule activators of the FOXO3 transcription factor for the treatment of age-related diseases. Today, the company ...

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, and a company of Danaher Corporation (NYSE: DHR), launches the Cydem VT Automated Clone Screening System, a ...

IHH Healthcare, one of the world’s largest private healthcare groups, is harnessing its unique global reach to deliver cutting-edge healthcare while championing sustainability. Hospitals are ...

Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class ...